NAPSRx

According to Thomson Reuters, the pharmaceutical industry’s sales will amount to $1 Trillion in 2014.

Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) has received FDA approval for Ferric Citrate (formerly known as Zerenex) to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Keytruda, developed by Merck is intended for patients with advanced melanoma and who are unresponsive to other therapies.

The new life science division of Google called Calico will join forces with Abbvie to collaborate on the discovery, development and commercialization of new therapies in a research deal worth approximately $1.5 billion.

Biotech giant Abbvie's collaborative deal with Infinity Pharmaceuticals to develop and market duvelisib is worth approximately $800 million.

ELELYSO is the first FDA-approved plant cell-based recombinant therapeutic protein and is currently marketed in the United States by Pfizer Inc.

Amgen is dedicated to discovering, developing, manufacturing and delivering innovative human therapeutics for patients with debilitating illnesses.

The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Promacta® developed by GlaxoSmithKline (GSK) to treat a rare bone marrow disorder.

Roche looks to expand their respiratory portfolio by acquiring InterMune Inc, a California based biotechnology company and their lead product pirfenidone for idiopathic pulmonary fibrosis (IPF).

ViiV Healthcare is a global specialist company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) specializing in the treatment and care for people living with HIV.